Olanzapine - Top U.S. Generic Blockbusters

Olanzapine
Branded drug: Zyprexa
U.S. sales: $921 million
Companies: Prasco Labs, $461 million; Teva, $459 million

There is big demand for generic Zyprexa, the bipolar, schizophrenia treatment from Eli Lilly ($LLY) that had been its biggest seller before going off patent in October 2011. Prasco Labs makes Lilly's authorized generic. Teva Pharmaceutical Industries ($TEVA) and partner Dr. Reddy's Laboratories got the nod for their copy last year. In just 8 of 12 months covered by this report, sales of the generic Zyprexa allowed Prasco and Teva to rank near the blockbuster range, according to data from IMS Health.

Due to safety questions, some highly publicized litigation and a $1.42 billion off-label marketing settlement in 2009, Zyprexa sales had started to falter for Lilly ahead of its 2011 patent expiration. Still it produced some monster sales numbers, and is now producing a monster-sized gap in Lilly's finances now that generics have arrived. In the first 9 months of this year, worldwide sales were down 68% to $1.3 billion and sales in the U.S. were down a breathtaking 88% to $300 million.

That hurts even more since Lilly continues to defend itself against more than three dozen lawsuits over its safety risks, including links to weight gain and diabetes. Lilly won the first case to go to trial with a jury determining that it had adequately warned patients of possible side effects.

For more:
Sales, profits fall short for Lilly's 'ho-hum' quarter
Report: Schizophrenia drug sales are shrinking, but growth will return
Pfizer, Lilly earnings drop on new generic rivals

Olanzapine - Top U.S. Generic Blockbusters
Read more on

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.